After First Psychotic Episode: Study Finds ‘Less Is More’ Psych Meds

A 1960s ad for the anti-psychotic drug Thorazine (Wikimedia Commons)

A 1960s ad for the anti-psychotic drug Thorazine (Wikimedia Commons)

It got a bit lost in the 4th-of-July whirl, but an intriguing study came out last week in the journal JAMA Psychiatry, suggesting that for long-term recovery from psychosis, it may be better — much better — to go lighter on the anti-psychotic drugs: Your chances of recovery could double.

As a JAMA Psychiatry editorial puts it, during the remission period that follows a first episode of psychosis, when it comes to antipsychotic drugs, “less is more.”

The study immediately made me think of Robert Whitaker’s 2011 book, “Anatomy of an Epidemic,” which presented evidence that in many cases, psychiatric drugs may do more long-term harm than good. Among other points, it notes some data suggesting that schizophrenics who take anti-psychotics fare worse, long-term, than those who don’t.

From the JAMA Psychiatry press release:

Dose reduction/discontinuation (DR) of antipsychotics during the early stages of remitted first-episode psychosis (FEP) shows higher long-term recovery rates compared with the rates achieved with maintenance treatment (MT), according to a study by Lex Wunderink, M.D., Ph.D., of Friesland Mental Health Services, Leeuwarden, the Netherlands, and colleagues.

This study was a follow up study of 128 patients who had participated in a two-year open randomized clinical trial comparing MT and DR from October 2001 to December 2002. After six months of remission, patients were randomly assigned to DR strategy or MT for 18 months, and after the trial, treatment was at the discretion of the physician. Researchers contacted patients 5 years after the trial had ended, and 103 patients consented to participate in a follow up interview about the course and outcomes of psychosis.

The DR patients (n=52) experienced twice the recovery rate of the MT patients (n=51) (40.4 percent versus 17.6 percent). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates, according to the study results.

“To our knowledge, this study is the first to identify major advantages of a DR strategy over MT in patients with remission of FEP.” The authors write, “the results of this study lead to the following conclusions: schizophrenia treatment strategy trials should include recovery or functional remission rates as their primary outcome and should also include long-term follow-up for more than 2 years, even up to 7 years or longer…benefits that were not evident in short-term evaluations, such as functional gains, only appeared during long-term monitoring.”

Readers? Ring true? Worry you that people who need meds may not take them?

Please follow our community rules when engaging in comment discussion on this site.
  • ronpies

    An interesting coda to the findings cited by Ms. Goldberg:

    Researchers with the Cochrane Schizophrenia Group at England’s
    University of Nottingham reported in the Cochrane Database of Systematic
    Review that intermittent antipsychotic therapy is less effective than
    long-term therapy in preventing episodic recurrences in individuals with

    The study analyzed data from multiple randomized trials—covering
    50 years—that evaluated relapse and hospitalization rates of 2,252
    patients undergoing intermittent or chronic therapy for schizophrenia
    or schizophrenia-like psychosis. The data showed that episodic
    recurrence and hospital readmission rates were higher among individuals
    receiving intermittent therapy than those receiving continuous
    maintenance treatment. However, intermittent therapy was more
    effective than placebo. [APA News Alert]

    Ronald Pies MD 8/24/13

  • ronpies

    The results of this study should be interpreted with great caution. First, the subjects were patients with first-episode psychosis, who had achieved remission for a half year. The results of the study may not apply to those who have had multiple psychotic episodes, or to patients with improvement but not full remission. Furthermore, it is important to note (as per the accompanying editorial) that at 18 months, there was twice the rate of relapse in the DR (dose-reduction/discontinuation) group as in those who continued on the antipsychotic medication (43 vs. 21%). The improved functional recovery for the DR group, evident after 7 years, is certainly important–but it does not tell us that eliminating antipsychotic medication is wise, for all patients, in the first few months after remission from psychosis. Of course, the lowest effective dose of these medications should always be used, with full informed consent of patients and/or guardians.

    Ronald Pies MD

  • Klaas

    Very true! Most, if not all psychiatric drugs do at best suppress some symptoms for a while, but generate drug dependence and increasing neurological damage on the long run.

    Which is then taken by “psychiatrists” as an argument that the mental illness of the patient has worsened and the patient should tot “treat” this, get higher doses of drugs or a second or even third drug.

    It is a destructive cycle that only makes the prescribers and manufacturers better.

  • Reasonable?

    Thanks so much for this article. I’m actually dealing with very issue right now.